Shares of Kymera Therapeutics Inc (NASDAQ:KYMR) climbed 8.8% in premarket trading after the company confirmed it had completed enrollment in its BROADEN2 Phase 2b trial for atopic dermatitis substantially earlier than planned.
Kymera said enrollment in the BROADEN2 study of KT-621 - its oral STAT6 degrader - finished nearly six months ahead of schedule. As a result, the company now plans to move its topline data readout forward by approximately six months, targeting year-end 2026 rather than the previously indicated mid-2027 timing.
The BROADEN2 study is designed as a global, randomized, double-blind, placebo-controlled Phase 2b trial. It is evaluating three dose levels of KT-621 in roughly 200 participants, including adults and adolescents aged 12 to 75, who have moderate to severe atopic dermatitis. The treatment period is 16 weeks, and the trial's primary endpoint is the percent change from baseline in the Eczema Area and Severity Index (EASI) score at Week 16.
Subject to discussions with regulators, Kymera stated it expects to begin Phase 3 trials in atopic dermatitis by mid-2027. In parallel, the company is running the BREADTH Phase 2b study of KT-621 in moderate to severe eosinophilic asthma, with topline data from that program anticipated in late 2027.
KT-621 is characterized by Kymera as a first-in-class, once-daily oral degrader of STAT6, the transcription factor that mediates IL-4 and IL-13 signaling and Type 2 inflammatory responses. The U.S. Food and Drug Administration has granted KT-621 Fast Track designation for both moderate to severe atopic dermatitis and eosinophilic asthma.
Kymera is a clinical-stage biopharmaceutical company focused on developing oral small-molecule degrader therapies for immunological diseases.
Context and implications
Faster-than-expected patient enrollment can shorten development timelines by bringing forward key readouts that inform later-stage trial planning and regulatory interactions. In this instance, Kymera’s accelerated recruitment enabled an advancement of the topline readout by six months, which the market interpreted positively in premarket trading.
What remains pending
While BROADEN2 enrollment is complete and the company has a revised readout timeframe, further steps - including regulatory discussions and initiation of Phase 3 trials - depend on upcoming data and regulator engagement. The BREADTH asthma study also remains on the company’s roadmap with a later data timing.